Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. 1977

J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz

To investigate the role of glucagon in regulating hepatic glucose production in man, selective glucagon deficiency was produced in four normal men by infusing somatostatin (0.9 mg/h) and regular pork insulin (150-muU/kg per min) for 2 h. Exogenous glucose was infused to maintain euglycemia. Arterial plasma glucagon levels fell by greater than 50% whereas plasma insulin levels were maintained in the range of 10-14 muU/ml. In response to these hormonal changes, net splanchnic glucose production (NSGP) fell by 75% and remained suppressed for the duration of the study. In contrast, when somatostatin alone was administered to normal men, resulting in combined insulin and glucagon deficiency (euglycemia again maintained), NSGP fell markedly but only transiently, reaching its nadir at 15 min. Thereafter, NSGP rose progressively, reaching the basal rate at 105 min. These data indicate that the induction of selective glucagon deficiency in man (with basal insulin levels maintained) is associated with a marked and sustained fall in hepatic glucose production. We conclude, therefore, that basal glucagon plays an important role in the maintenance of basal hepatic glucose production in normal man.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz
November 1976, Metabolism: clinical and experimental,
J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz
April 1980, The Journal of clinical endocrinology and metabolism,
J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz
January 1997, Canadian journal of physiology and pharmacology,
J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz
January 1979, Diabetes,
J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz
May 1982, The Journal of clinical endocrinology and metabolism,
J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz
June 1994, Clinical nutrition (Edinburgh, Scotland),
J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz
March 1977, The Journal of clinical endocrinology and metabolism,
J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz
March 1982, Metabolism: clinical and experimental,
J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz
December 1979, The Journal of clinical endocrinology and metabolism,
J E Liljenquist, and G L Mueller, and A D Cherrington, and U Keller, and Chiasson J-L, and J M Perry, and W W Lacy, and D Rabinowitz
January 1980, The American journal of physiology,
Copied contents to your clipboard!